ClinicalTrials.gg

Program

anumigilimab

Also written as “CSL324” and “Anumigilimab”.

Its studies are mostly in Anemia, Sickle Cell · COVID-19, led by CSL.

Furthest: phase 2, since Aug 18, 20204 company-led studies, 1 open or runningNext primary completion: Aug 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL41 open or runningphase 2since Aug 18, 2020Aug 18, 2020Aug 15, 2028phase 2 · NCT07224360

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2020First study: phase 2 study in COVID-19First studyNCT04519424
  2. Sep 25, 2020Phase 1 study in HealthyNCT04570267 · 32 enrolled · Australia
  3. Dec 8, 2022Phase 1 study in Healthy VolunteersNCT05653713 · 40 enrolled · Germany
  4. Oct 31, 2025Phase 2 study in Anemia, Sickle CellNCT07224360 · 63 planned · United States, Belgium, France and more

Ahead

  1. Aug 15, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT07224360

TargetBeta

CSF3R →read by rule
“Granulocyte colony stimulating factor receptor antagonist”ChEMBL 37, by rule

Other programs on CSF3R

ProgramCompanyFurthest phaseStudies
pegfilgrastimruleAmgenphase 452
FilgrastimrulePfizerphase 433

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07224360Anemia, Sickle Cell · United States, Belgium, France and more2RecruitingAug 15, 202863
NCT05653713Healthy Volunteers · Germany1CompletedJul 21, 202340
NCT04570267Healthy · Australia1CompletedNov 17, 202132
NCT04519424COVID-192WithdrawnApr 20210

How it is read

Names in the registry

  • “CSL324”, 3 entries
  • “Anumigilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
anumigilimab (CSL): development program | ClinicalTrials.gg